🏛️ Verified NIH Record • Updated 2026-08-05
Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics (NCT07758231)
🟡 Not Yet Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: University of Wisconsin, Madison
🩺 Plain-English Summary (8th-Grade Level)
This study is to learn how the weight loss drug tirzepatide (Zepbound) changes the way a body handles alcohol. 5 participants aged 21-55 who take Zepbound will be enrolled and can expect to be on study for up to 4 weeks.
Who can join: Review the eligibility criteria below.
Location: University of Wisconsin — Madison, Wisconsin
Age range: 21 Years to 55 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of Wisconsin — Madison, Wisconsin
📞 Contact the Study Coordinator
Phone: (608) 890-1967
Email: hbarkholtz@wisc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All GLP-1 clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.